Raph Hamers

Senior Clinician Scientist


  • PhD from the University of Amsterdam

Raph Hamers is an internist and infectious disease physician. His research to date has been centred on the clinical management, epidemiology and public health aspects of HIV, particularly drug-resistant HIV and chronic immune dysregulation, with over 10 years of experience in research projects in sub-Saharan Africa.


  • HIV and opportunistic infections
  • Tuberculosis
  • Antimicrobial drug resistance
  • Diagnostics
  • Multidisciplinary approaches to improve health outcomes in low-resource settings


  • Post-doctoral fellowship from the Netherlands Organization for Scientific Research through the Innovational Research Incentives Scheme (Veni)
  • Honorary positions at the Academic Medical Center, University of Amsterdam.


  1. Surveillance strategies using routine microbiology for antimicrobial resistance in low and middle-income countries.
    Clin Microbiol Infect. 2021 Jun 7. pii: S1198-743X(21)00285-8. doi: 10.1016/j.cmi.2021.05.037.
  2. A multicentre point prevalence survey of patterns and quality of antibiotic prescribing in Indonesian hospitals.
    JAC Antimicrob Resist. 2021 Apr 26;3(2):dlab047. doi: 10.1093/jacamr/dlab047. eCollection 2021 Jun.
  3. 2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings.
    J Antimicrob Chemother. 2021 Apr 1. pii: 6207542. doi: 10.1093/jac/dkab078.
  4. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study.
    Lancet Reg Health West Pac. 2021 Apr;9:100108. doi: 10.1016/j.lanwpc.2021.100108. Epub 2021 Mar 2.
  5. Plasma inflammatory biomarkers predict CD4+ T-cell recovery and viral rebound in HIV-1 infected Africans on suppressive antiretroviral therapy.
    J Infect Dis. 2020 Dec 29. pii: 6054994. doi: 10.1093/infdis/jiaa787.
  6. Is increasing pretreatment HIV drug resistance a real menace or minor detail?
    Lancet HIV. 2020 May;7(5):e316-e317. doi: 10.1016/S2352-3018(20)30048-5.
  7. Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens.
    Lancet Infect Dis. 2019 Mar 19. pii: S1473-3099(18)30710-2. doi: 10.1016/S1473-3099(18)30710-2.
  8. Dolutegravir for second-line antiretroviral therapy.
    Lancet Infect Dis. 2019 Mar;19(3):218-219. doi: 10.1016/S1473-3099(19)30035-0. Epub 2019 Feb 4.
  9. Dolutegravir in sub-Saharan Africa: context is crucial.
    Lancet HIV. 2019 Feb;6(2):e72-e73. doi: 10.1016/S2352-3018(18)30331-X. Epub 2018 Nov 29.
  10. HIV drug resistance in low-income and middle-income countries.
    Lancet HIV. 2018 Oct;5(10):e588-e596. doi: 10.1016/S2352-3018(18)30173-5. Epub 2018 Sep 4.
  11. What the WHO's List of Essential Diagnostics means for clinical microbiology laboratories and antimicrobial stewardship practice worldwide.
    Clin Microbiol Infect. 2019 Jan;25(1):6-9. doi: 10.1016/j.cmi.2018.08.013. Epub 2018 Aug 24.
  12. Adjunctive dexamethasone for the treatment of HIV-infected adults with tuberculous meningitis (ACT HIV): Study protocol for a randomised controlled trial.
    Wellcome Open Res. 2018 Jun 20;3:31. doi: 10.12688/wellcomeopenres.14006.2. eCollection 2018.
  13. Antibiotic consumption in low-income and middle-income countries.
    Lancet Glob Health. 2018 Jul;6(7):e732. doi: 10.1016/S2214-109X(18)30270-5.
  14. HIV Drug Resistance.
    N Engl J Med. 2018 Mar 1;378(9):873-4. doi: 10.1056/NEJMc1716089.